← Back to Screener
BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT)
Price$7.81
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-44.48%
Price vs S&P 500 (4W)1.97%
VGM Score32.56
Market Capitalization$625.64M
P/E Ratio (Annual)82.33x
All Metrics
Book Value / Share (Quarterly)$8.05
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)-45.78%
EPS (TTM)$0.20
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$0.20
EPS (Annual)$0.36
ROI (Annual)4.03%
Cash / Share (Quarterly)$0.03
P/E Basic Excl Extra (TTM)132.62x
P/E Normalized (Annual)82.33x
ROA (Last FY)3.91%
EBITD / Share (TTM)$-0.17
Cash Flow / Share (Annual)$-0.03
P/B Ratio3.31x
P/B Ratio (Quarterly)1.32x
ROA (TTM)2.42%
EPS Growth QoQ (YoY)-58.45%
EPS Incl Extra (Annual)$0.36
Current Ratio (Annual)10.40x
Quick Ratio (Quarterly)0.25x
3-Month Avg Trading Volume0.32M
52-Week Price Return-28.28%
P/E Incl Extra (TTM)132.62x
52-Week High$14.87
EPS Excl Extra (Annual)$0.36
26-Week Price Return-36.56%
Quick Ratio (Annual)9.05x
13-Week Price Return-21.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.33x
Enterprise Value$624.97M
Cash / Share (Annual)$0.07
3-Month Return Std Dev55.38%
ROE (Last FY)4.03%
EPS Basic Excl Extra (Annual)$0.36
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.20
ROI (TTM)2.51%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-52.65%
P/E Ratio (TTM)132.62x
EPS Growth TTM (YoY)18.80%
Year-to-Date Return-37.62%
5-Day Price Return-8.65%
EPS Normalized (Annual)$0.36
Month-to-Date Return-12.93%
EBITD / Share (Annual)$-0.03
P/E Excl Extra (TTM)132.62x
EPS Basic Excl Extra (TTM)$0.20
P/B Ratio (Annual)1.33x
Book Value / Share (Annual)$8.03
Price vs S&P 500 (13W)-29.29%
Beta0.50x
Revenue / Share (TTM)$0.00
ROE (TTM)2.51%
52-Week Low$7.60
gGradeD
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.53est. -0.54
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock | — | D | D | $7.81 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing cancer therapies that target RAS and PI3Ka mutations, two of the most frequently mutated oncogenic drivers. The company aims to address unmet needs in oncology by creating targeted treatments for patients with these genetically-driven cancers.